Experimental validation and pan-cancer analysis identified COL10A1 as a novel oncogene and potential therapeutic target in prostate cancer
Figure 11. Immunotherapy analysis of melanoma (A), renal cancer (B), and urothelial epithelial tumor (C) in data from the GSE78220 (A), GSE67501 (B), and IMvigor210 database (C).